SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-17-002506
Filing Date
2017-04-11
Accepted
2017-04-11 16:15:25
Documents
5
Period of Report
2017-05-17
Effectiveness Date
2017-04-11

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2231747zdef14a.htm DEF 14A 732410
2 G548486.JPG g548486.jpg GRAPHIC 17173
3 G971103.JPG g971103.jpg GRAPHIC 4111
4 G21732BCI001.JPG g21732bci001.jpg GRAPHIC 228530
5 G21732BCI002.JPG g21732bci002.jpg GRAPHIC 120423
  Complete submission text file 0001047469-17-002506.txt   1243852
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36033 | Film No.: 17756079
SIC: 2834 Pharmaceutical Preparations